MPNs

Genomic Testing Should Be Standard in Myelofibrosis at Diagnosis, Says Rampal

September 22, 2020

Raajit K. Rampal, MD, PhD, discussed the role of genomics in the treatment landscape of myelofibrosis and the remaining challenges that need to be addressed in order to use this information more effectively to treat patients and improve outcomes.

Virtual Medical Meetings Open Up Online Communication for Myeloproliferative Neoplasms

September 18, 2020

In an interview with Targeted Oncology, Naveen Pemmaraju, MD, discussed recent advances for the treatment of patients with MPNs and shared his thoughts on recent hematologic meetings and the growing role of social media during the COVID-19 pandemic.

Treatment Approaches Become More Individualized as Field of Myelofibrosis Advances

September 15, 2020

Ruben Mesa, MD, shares highlights from his presentation on the role of JAK inhibitors in myelofibrosis during the first annual Texas Virtual MPN Workshop and Meeting.

Expert Reviews the Current State of the Essential Thrombocythemia Treatment Paradigm

September 14, 2020

In an interview with Targeted Oncology, Prithviraj Bose, MD, discussed the disease outcomes for patients with essential thrombocythemia, as well as the unmet needs and therapeutic strategies available in this space.

Prognostic Factors Suggest Benefit for Some With Myeloablative Busulfan/Fludarabine Conditioning in Myelofibrosis

September 10, 2020

Prognostic factors in patients with myelofibrosis treated with a myeloablative busulfan/fludarabine conditioning regimen prior to allogeneic stem cell transplantation in a single-institution analysis showed that a time from diagnosis to transplant of more than 12 months was associated with poorer overall survival and displayed a trend toward higher non-relapse mortality.

JAK Inhibition Shakes Up MPN Paradigm With 2 Potential Additions to the Armamentarium

September 10, 2020

JAK inhibitors continue to make a splash in the treatment landscape of MPNs and are be evaluated in multiple clinical trials, and the advancement of these agents should be recognized in honor of MPN Awareness Day.

Moving Beyond JAK Inhibitors in Myeloproliferative Neoplasms

September 07, 2020

Naveen Pemmaraju, MD, discusses the need to move beyond JAK inhibition when treating patients with myeloproliferative neoplasms.

Novel Targets Outside of JAK Inhibition Inching into Myelofibrosis Treatment Landscape

August 31, 2020

Experts in myeloproliferative neoplasms find janus kinase inhibitors to be particularly important to the armamentarium for the treatment of myelofibrosis. With only 2 FDA-approved agents, fedratinib and ruxolitinib, and the inevitability that not all patients will derive benefit, and some will develop resistance, the option of moving beyond JAK inhibition is widely discussed.

Targeted Therapy Combinations With JAK inhibition Show Early Promise for Myelofibrosis

August 31, 2020

Patients with myelofibrosis have complicated pathology and multiple pathways, creating the opportunity to use multiple targeted agents for treatment, but also leading to greater potential for resistance to monotherapy, according to Lucia Masarova, MD.

Targeted Approach Considered for the Treatment of Accelerated/Blast Phase MPNs

August 31, 2020

Standard treatment for accelerated or blast phase myeloproliferative neoplasms consists of hypomethylating agents or intensive induction chemotherapy and transplant. However, newer studies have suggested that accelerated or blast phase MPNs, such as acute myeloid leukemia, can be treated with molecularly driven targeted therapies.